Recent research introduces risk nomograms to predict overall survival in prostate cancer over three, five, and seven years, utilizing PROMISE and PPP3 assessments.
Recent findings have unveiled new risk nomograms created by PROMISE, enabling healthcare professionals to predict overall survival rates in prostate cancer patients at three, five, and seven years. These assessments, known as PROMISE and PPP3, are designed for global use and are freely accessible online. This initiative aims to enhance prognostic capabilities in the management of prostate cancer, allowing better-informed decisions in patient care.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.